- Trials with a EudraCT protocol (69)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
69 result(s) found for: CD5.
Displaying page 1 of 4.
| EudraCT Number: 2013-000506-37 | Sponsor Protocol Number: ECWM-1 | Start Date*: 2014-10-31 |
| Sponsor Name:University Hospital Ulm | ||
| Full Title: Efficacy of first line Dexamethasone, Rituximab and Cyclophosphamide (DRC) +/- Bortezomib for patients with Waldenström's Macroglobulinemia | ||
| Medical condition: Waldenström's Macroglobulinemia | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: CZ (Completed) IT (Ongoing) PT (Prematurely Ended) SE (Completed) GR (Completed) ES (Ongoing) | ||
| Trial results: View results | ||
| EudraCT Number: 2005-001502-11 | Sponsor Protocol Number: ML18434 | Start Date*: 2005-07-18 |
| Sponsor Name:Roche Austria GmbH | ||
| Full Title: “CHAIROS” – Early brief intensification by chemoimmunotherapy with FCR followed by FR and Rituximab maintenance in chemonaive patients with B-CLL – A phase II study | ||
| Medical condition: Chronic lymphocytic leukemia (CLL) | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: AT (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2006-001965-41 | Sponsor Protocol Number: BRD/06/052 | Start Date*: 2008-09-05 |
| Sponsor Name:University College London | ||
| Full Title: Phase III, multicentre, randomised study of fludarabine/cyclophosphamide combination with or without Rituximab in patients with untreated mantle cell lymphoma | ||
| Medical condition: Mantle Cell Lymphoma | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: GB (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2007-004824-19 | Sponsor Protocol Number: ML21206 | Start Date*: 2008-08-08 |
| Sponsor Name:Roche Austria GmbH | ||
| Full Title: Bevacizumab in Chronic Lymphocytic Leukemia: a proof of concept study | ||
| Medical condition: Chronic Lymphocytic Leukemia | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: AT (Prematurely Ended) | ||
| Trial results: View results | ||
| EudraCT Number: 2010-022681-27 | Sponsor Protocol Number: O-DEX-1 | Start Date*: 2010-11-09 |
| Sponsor Name:University Hospital Brno | ||
| Full Title: Ofatumumab Added to Dexamethasone in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia | ||
| Medical condition: Patients with refractory/relapsed CLL | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: CZ (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2004-004741-17 | Sponsor Protocol Number: SPC2996-101 | Start Date*: 2005-05-09 |
| Sponsor Name:Santaris Pharma | ||
| Full Title: SPC2996 in Chronic Lymphocytic Leukaemia An open-labelled, international multicenter dose escalating, phase I/II study of SPC2996, an LNA antisense molecule against Bcl-2, in patients with relapsed... | ||
| Medical condition: Chronic Lymphocytic Leukaemia (CLL) is the most common leukaemia in adults in the US and most of Western Europe. The incidence is 8100 to 12500 new cases in the US per year. CLL is a relatively ind... | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: DK (Prematurely Ended) GB (Prematurely Ended) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2005-003761-16 | Sponsor Protocol Number: 9818P | Start Date*: 2005-11-24 |
| Sponsor Name:Department of R & D, Central Manchester and Manchester Children's Hospital NHS Trust | ||
| Full Title: Evaluation of pneumococcal conjugate vaccine (Prevenar) in patients with myeloma and chronic lymphocytic leukaemia | ||
| Medical condition: Pneumococcal disease is a common form of meningitis, septicaemia and pneumonia. Those individuals at highest risk include children, the elderly and persons whose immune systems are impaired. This l... | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: GB (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2012-000933-37 | Sponsor Protocol Number: CRT113890 | Start Date*: 2012-09-18 |
| Sponsor Name:National and Kapodostrian University of Athens | ||
| Full Title: Phase II trial of ofatumumab combined with ESHAP as salvage therapy before autologous stem cell transplantation, for patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL) previ... | ||
| Medical condition: Relapsed or refractory diffuse large B cell lymphoma (DLBCL). | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: GR (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2012-003631-36 | Sponsor Protocol Number: RG_12-124 | Start Date*: 2015-02-10 | |||||||||||
| Sponsor Name:University of Birmingham | |||||||||||||
| Full Title: CALiBRe: Assessment of the Mechanism of Action of idelalisib (CAL-101) in B-cell Receptor Pathway Inhibition in CLL | |||||||||||||
| Medical condition: Chronic lymphocytic leukaemia | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2007-003081-18 | Sponsor Protocol Number: BRD/07/137 | Start Date*: 2008-09-29 |
| Sponsor Name:University College Hospital | ||
| Full Title: Phase II study of low intensity allogeneic transplantation in Mantle Cell Lymphoma | ||
| Medical condition: Mantle Cell Lymphoma (MCL) is an increasingly recognised yet rare sub-type of non-hodgkin's Lymphoma (NHL), representing between 5 and 8% of all cases. Typically a disease of the elderly with a me... | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: GB (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2010-024389-23 | Sponsor Protocol Number: 114813 | Start Date*: 2011-06-07 |
| Sponsor Name:Department of Hematology | ||
| Full Title: A Phase 2 Trial of Alemtuzumab-Ofatumumab Combination in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia | ||
| Medical condition: Chronic Lymphocytic Leukemia | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: SE (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2017-000129-12 | Sponsor Protocol Number: PCYC-1143-CA | Start Date*: 2017-10-10 | |||||||||||
| Sponsor Name:Pharmacyclics LLC | |||||||||||||
| Full Title: Phase 3 Study of Ibrutinib in Combination with Venetoclax in Subjects with Mantle Cell Lymphoma | |||||||||||||
| Medical condition: Mantle Cell Lymphoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) CZ (Completed) DE (Completed) BE (Completed) HU (Completed) ES (Ongoing) NL (Completed) GR (Completed) IT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2017-004362-95 | Sponsor Protocol Number: ECWM-2 | Start Date*: 2019-04-12 | |||||||||||
| Sponsor Name:University Hospital Ulm | |||||||||||||
| Full Title: Efficacy of first line Bortezomib, Rituximab, Ibrutinib (B-RI) for patients with treatment naive Waldenström’s Macroglobulinemia | |||||||||||||
| Medical condition: Waldenström's Macroglobulinemia | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Trial now transitioned) GR (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2012-004056-11 | Sponsor Protocol Number: PCI-32765MCL3002 | Start Date*: 2014-01-30 | |||||||||||
| Sponsor Name:Janssen-Cilag International NV | |||||||||||||
| Full Title: A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination with Bendamustine and Rituximab (BR) in Subjects ... | |||||||||||||
| Medical condition: Mantle Cell Lymphoma | |||||||||||||
|
|||||||||||||
| Population Age: Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: SE (Completed) BE (Completed) GB (GB - no longer in EU/EEA) DE (Completed) HU (Completed) IE (Completed) IT (Completed) PT (Prematurely Ended) SK (Completed) ES (Ongoing) NL (Completed) FR (Completed) PL (Completed) CZ (Completed) GR (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2013-002110-12 | Sponsor Protocol Number: GO28667 | Start Date*: 2014-02-26 | |||||||||||
| Sponsor Name:AbbVie Deutschland GmbH & Co. KG | |||||||||||||
| Full Title: A MULTICENTER, PHASE III, OPEN-LABEL, RANDOMIZED STUDY IN RELAPSED/REFRACTORY PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA TO EVALUATE THE BENEFIT OF GDC-0199 (ABT-199) PLUS RITUXIMAB COMPARED WITH... | |||||||||||||
| Medical condition: Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: CZ (Completed) SE (Completed) BE (Completed) GB (GB - no longer in EU/EEA) AT (Completed) IT (Completed) FR (Completed) NL (Completed) HU (Completed) DK (Completed) DE (Completed) ES (Completed) PL (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2015-004454-17 | Sponsor Protocol Number: ACE-CL-309 | Start Date*: 2016-10-24 | |||||||||||
| Sponsor Name:Acerta Pharma BV | |||||||||||||
| Full Title: A Randomized, Multicenter, Open-Label, Phase 3 Study of Acalabrutinib (ACP-196) Versus Investigator’s Choice of Either Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Subjects with Rela... | |||||||||||||
| Medical condition: Relapsed or Refractory Chronic Lymphocytic Leukemia | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: BE (Completed) HU (Trial now transitioned) SK (Completed) SE (Completed) ES (Ongoing) CZ (Trial now transitioned) AT (Completed) DE (Completed) FR (Completed) BG (Completed) PL (Trial now transitioned) HR (Trial now transitioned) IT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2018-002443-28 | Sponsor Protocol Number: ACE-CL-311/D8221C00001 | Start Date*: 2019-05-08 | |||||||||||
| Sponsor Name:Acerta Pharma B.V. | |||||||||||||
| Full Title: A Randomized, Multicenter, Open-Label, Phase 3 Study to Compare the Efficacy and Safety of Acalabrutinib (ACP-196) in Combination with Venetoclax with and without Obinutuzumab Compared to Investiga... | |||||||||||||
| Medical condition: Previously untreated Chronic Lymphocytic Leukemia Without del(17p) or TP53 Mutation | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Restarted) HU (Trial now transitioned) CZ (Trial now transitioned) SK (Trial now transitioned) PL (Trial now transitioned) GB (GB - no longer in EU/EEA) FR (Trial now transitioned) DK (Trial now transitioned) SE (Trial now transitioned) BG (Trial now transitioned) NL (Trial now transitioned) DE (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2005-006163-31 | Sponsor Protocol Number: Hx-CD20-406 | Start Date*: 2006-05-16 | |||||||||||
| Sponsor Name:Genmab A/S | |||||||||||||
| Full Title: A single-arm, international, multi-center trial of HuMax-CD20, a fully human monoclonal anti-CD20 antibody, in patients with B-cell Chronic Lymphocytic Leukemia who have failed fludarabine and alem... | |||||||||||||
| Medical condition: B-cell Chronic Lymphocytic Leukemia | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Completed) SE (Completed) DE (Completed) CZ (Completed) DK (Completed) ES (Completed) NL (Prematurely Ended) IT (Completed) BE (Completed) AT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2014-005024-10 | Sponsor Protocol Number: I6F-MC-JJCB | Start Date*: 2015-07-29 |
| Sponsor Name:Eli Lilly and Company | ||
| Full Title: A Phase 1b/Randomized Phase 2 Study to Evaluate LY3039478 in Combination with Dexamethasone in T-ALL/T-LBL Patients | ||
| Medical condition: T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LBL) | ||
| Disease: | ||
| Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
| Trial protocol: DE (Completed) SE (Completed) IT (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2008-005811-16 | Sponsor Protocol Number: OMB110913 | Start Date*: 2008-12-22 |
| Sponsor Name:GlaxoSmithKline Research and Development Limited | ||
| Full Title: A Phase III, Open Label, Randomized Trial of Ofatumumab Added to Fludarabine-Cyclophosphamide vs. Fludarabine-Cyclophosphamide Combination in Subjects with Relapsed Chronic Lymphocytic Leukemia | ||
| Medical condition: Chronic Lymphocytic Leukaemia | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: NL (Completed) DE (Completed) GR (Completed) IT (Completed) ES (Completed) GB (Completed) BG (Completed) RO (Completed) | ||
| Trial results: View results | ||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.
